Eli Lilly & Co. v. Arla Foods, Inc., No. 17-2252, 2018
WL 2998510, -- F.3d – (7th Cir. Jun. 15, 2018)
Arla launched a $30 million advertising campaign aimed at
expanding its cheese sales in the US, using the theme “Live Unprocessed.” The ads promise that Arla cheese contains no “weird
stuff” or “ingredients that you can’t pronounce”—in particular, no milk from
cows treated with recombinant bovine somato-tropin (rbST), an artificial growth
hormone. “The flagship ad in the campaign features a vivid rhetorical flourish
implying that milk from rbST-treated cows is unwholesome.” The ad opens with a
caption: “Arla Cheese Asked Kids: What is r[b]ST?” A cartoon of a six-eyed
monster and a fisherman appears and a seven-year-old girl named Leah narrates:
“RbST has razor sharp horns. It’s so tall that it could eat clouds. You may
want to pet it but the fur is electric.” The commercial then cuts to Leah
enjoying a cheese sandwich, and an adult woman narrates: “Actually, rbST is an
artificial growth hormone given to some cows, but not the cows that make Arla
cheese. No added hormones. No weird stuff. Arla, live unprocessed.” A small
written disclaimer appears for a few seconds toward the end of the commercial:
“Made with milk from cows not treated with r[b]ST. No significant difference
has been shown between milk derived from r[b]ST-treated and non r[b]ST-treated
cows.”
And razor teeth |
Arla defined “weird stuff” on its website:
No artificial additives. No
ingredients that you can’t pronounce. No ingredients that sound confusing or in
any way like a made-up word. No ingredients with names that sound like they may
be aliens with nine arms, beasts with electric fur, gigantic robots[,] or bears
in dis-guise. No artificial growth hormones like r[b]ST.* ... Nor anything else
artificial[ ] because our cheese has always been made with simple ingredients
and never anything weird.
The asterisk directs readers to another part of the website
containing the same disclaimer that appears in small print in the television
commercial.
Eli Lilly makes the only FDA-approved rbST supplement; it
sued for false advertising, and won a preliminary injunction. The court of
appeals affirmed, holding that “[c]onsumer surveys or other ‘hard’ evidence of
actual consumer confusion are unnecessary at the preliminary-injunction stage.” Its evidence of harm included confidential
evidence that a major cheese producer chose to terminate its use of rbST
partially in response to Arla’s ads.
The trial judge found that milk from rbST-treated cows is
equally safe and healthy for human consumption as other milk, something that
Arla conceded for purposes of the appeal.
In a footnote, the court of appeals said that Arla would have trouble
fighting on safety and health for humans anyway, since the FDA twice confirmed
the safety of rbST-derived dairy products. A joint panel of the United Nations
and World Health Organization also found “no evidence to suggest that the use
of rbSTs would result in a higher risk to human health.” [But see International
Dairy Foods Assoc. v. Boggs, finding that a ban on no-rbST claims violated
the First Amendment and that there was evidence that milk from treated cows was
compositionally inferior to milk from untreated cows.]
“A literally false statement will necessarily deceive
consumers, so extrinsic evidence of actual consumer confusion is not required.”
However, Arla’s ads didn’t make explicitly false claims about the composition or
dangers of milk from rbST-treated cows. “Indeed, the explicit statements about
rbST are factually accurate: RbST is an artificial growth hormone given to some
cows, and Arla does not use milk from those cows.” Nonetheless, proof of actual
deception isn’t required at the preliminary injunction stage. “It’s not feasible to require a Lanham Act
plaintiff to conduct full-blown consumer surveys in the truncated timeframe
between filing suit and seeking a preliminary injunction.” Eli Lilly’s evidence from the ads themselves,
evidence about the quality of milk from treated cows, and evidence of decreased
demand were enough to show likely success on the merits without a consumer
survey.
“[T]he ad campaign centers on disparaging dairy products
made from milk supplied by rbST-treated cows.…The use of monster imagery, ‘weird
stuff’ language, and child actors combine to colorfully communicate the message
that responsible consumers should be concerned about rbST-derived dairy
products.” [Put that way, it sounds like another court could have found puffery. I understand the impulse to protect against vague
disparagement, but it is worth noting that the court doesn’t ask very much
about what factual message exactly consumers will take away.] It was reasonable to find these ads likely to
mislead.
The court of appeals also took comfort from FDA guidance warning
that ads about rbST-free milk products “may be misleading if not placed ‘in
proper context,’” including the disclaimer: “No significant difference has been
shown between milk derived from rbST-treated and non-rbST-treated cows.” Arla’s
ads put that disclaimer only in tiny print in the tv ad and in an “obscure
location” on the webpage. “Neither disclaimer dispels the central message of
these advertisements: that cheese made from milk supplied by rbST-treated cows
is unwholesome.”
Evidence of decreased demand from a major cheese producer
didn’t show actual confusion, but “given the cheese producer’s economic
incentive to accurately predict consumer demand, its concern about the ad
campaign’s impact on consumers supports the judge’s conclusion.” This also made causation an easy question,
since any false or misleading advertising regarding rbST that decreases demand
for the supplement would necessarily harm Eli Lilly, the sole US supplier.
The court of appeals also approved of a modified injunction preventing Arla from disseminating any ad substantially similar to the accused ones that “claims, either directly or by implication,” that rbST is anything other than an artificial hormone that prolongs the lactation of dairy cows. That was specific enough, in the context of the rest of the order. The injunction also barred any ad that claims, “either directly or by implication,” that “consumers should not feel ‘good about eating’ or ‘serving to [their] friends and family’ dairy products made from milk of cows supplemented with rbST. That still allowed Arla to make claims about its own products; “[t]he prohibited negative inference can arise only if an Arla advertisement specifically mentions rbST … in a disparaging way.” [Nice to know that the Seventh Circuit is still really, really confident in its consumer-predicting prowess.]
Judge Rovner concurred, agreeing that no proof of confusion
was required at this stage but declining to address the other merits of the
Lanham Act claim.